Suzlon Energy has bagged 21 MW order from a biotech major - Serum Institute of India. The order is to supply 10 turbines of 2.1 MW capacity each for captive consumption. As per the agreement, the company will supply, set up, operate and maintain the S88 wind turbines for Serum Institute in Pune.
Serum Institute of India is a leading biotech company and among the world's largest makers of pediatric vaccines as well as of measles and DTP group of vaccines. After awarding the contract the total renewable energy portfolio of the biotech company will increase to 60 MW.
Suzlon Group comprises of Suzlon Energy and its subsidiaries, including REpower Systems SE. Suzlon Energy is leader in wind energy in the India, which is world’s fifth largest wind energy market. Its business model has range of services that include development, manufacturing, marketing, EPC project delivery and operations and maintenance of wind turbine generators around the world.
DISCLAIMER: Accord Fintech provides the Content on “AS IS” basis without any express or implied warranties. Accord Fintech does not warrant the accuracy, timeliness, completeness, adequacy, merchantability, or fitness for a particular purpose of the Content, and Accord Fintech shall not be liable to Licensee or to any third party with respect to any actual or alleged inaccuracy, untimeliness, incompleteness, inadequacy, unmerchantbailty or unfitness.
Copyright 2012 Accord Fintech Pvt. Ltd., distributed by Contify.com